Illimis therapeutics Logo (WIPO, 03/17/2022)
WIPOProtect this trademark from copycats!
With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.
The International trademark Illimis therapeutics was filed as Figurative mark on 03/17/2022 at the World Intellectual Property Organization.
Logodesign (Wiener Klassifikation)
#Letters presenting a special form of writing #Colours #Series of letters presenting different forms of writing #Series of letters in different dimensions #Two predominant colours
| Trademark form | Figurative mark |
| File reference | 1665604 |
| Countries | 
|
| Base trademark |
No. ,
October 22, 2024
|
| Application date | March 17, 2022 |
| Expiration date | March 17, 2032 |
Trademark owner
2nd, 3rd Fl, 18, Heolleung-ro 569-gil,
Gangnam-gu
KR
Gangnam-gu
KR
Trademark representatives
A-302, USPACE2, Daewangpangyo-ro 670,
Bundang-gu, Seongnam-si
KR
goods and services
05
Pharmaceutical preparations for the treatment of auto-immune
diseases; pharmaceutical agents affecting sensory organs;
pharmaceutical agents affecting peripheral nervous system;
pharmaceutical preparations for activating cellular
function; pharmaceutical preparations acting on the central
nervous system; pharmaceutical preparations for respiratory
organs; pharmaceutical preparations for the prevention of
disorders of the nervous system; pharmaceutical preparations
for the treatment of cardiovascular disease;
pharmaceuticals; pharmaceutical preparations for the
treatment of inflammatory diseases; ophthalmic preparations;
pharmaceutical preparations for the treatment of eye
diseases and conditions; pharmaceutical preparations for the
treatment of degenerative brain disease; pharmaceutical
preparations for the treatment of brain dysfunction;
pharmaceutical preparations for the treatment of stroke;
pharmaceutical preparations for the treatment of
cerebrovascular disease; pharmaceutical preparations for the
treatment of dementia; pharmaceutical preparations for the
treatment of Alzheimer's disease; pharmaceutical
preparations for use in the treatment of solid tumors and
growths, hemolytic diseases and disorders, amyloidosis,
metabolic diseases and disorders, lupus, and inflammation
and autoimmune diseases and disorders
42
Pharmaceutical products development; research and
development in the field of age-related diseases/disorders
and degenerative diseases; research and development in the
field of chronic malady/disease and dysfunction; scientific
research in the field of gene therapy; medical scientific
research in the field of brain disease; medical scientific
research in the field of neurological diseases; research in
biotechnology and antibody fields; biological research;
scientific research in the field of cancer disease;
monitoring and inspection for quality control and analysis
of active substances in the pharmaceutical research field;
research for quality inspection related to human hygiene
management for medical research purposes; research of
autoimmune disease; development of cell therapy; stem cell
collection for medical research; cell processing and culture
for medical research; research and development in the field
of inflammatory disease; research and development in the
field of eye disease; research and development in the field
of amyloidosis; consultancy and information services
relating to pharmaceutical quality control
Trademark history
| Date | Document number | Area | Entry |
|---|---|---|---|
| May 10, 2023 | 2023/19 Gaz | CH | Rejection |
| March 30, 2023 | 2023/18 Gaz | KR | RAW: Partial Ceasing Effect |
| March 16, 2023 | 2023/11 Gaz | JP | Rejection |
| February 27, 2023 | 2023/9 Gaz | US | Rejection |
| November 3, 2022 | 2022/44 Gaz | EM | Rejection |
| September 30, 2022 | 2022/41 Gaz | RAW: Limitation | |
| September 23, 2022 | 2022/39 Gaz | CN | Rejection |
| September 8, 2022 | 2022/36 Gaz | GB | Rejection |
| March 17, 2022 | 2022/21 Gaz | KR | Registration |
ID: 141665604